Literature DB >> 30430398

Daptomycin-associated myopathy induced by concomitant administration of mirabegron.

Hideharu Hagiya1, Ryohei Kokado2,3, Hideo Okuno2, Kazunori Tomono2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30430398     DOI: 10.1007/s15010-018-1252-z

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  5 in total

Review 1.  Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.

Authors:  Pradeep Tyagi; Vikas Tyagi
Journal:  IDrugs       Date:  2010-10

2.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

3.  Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.

Authors:  Arcangelo Sebastianelli; Giorgio I Russo; Steven A Kaplan; Kevin T McVary; Ignacio Moncada; Stavros Gravas; Christopher Chapple; Giuseppe Morgia; Sergio Serni; Mauro Gacci
Journal:  Int J Urol       Date:  2017-12-03       Impact factor: 3.369

Review 4.  Daptomycin.

Authors:  Mohsen Heidary; Azar Dohkt Khosravi; Saeed Khoshnood; Mohammad Javad Nasiri; Saleh Soleimani; Mehdi Goudarzi
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

5.  Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.

Authors:  Ryan K Dare; Chad Tewell; Bryan Harris; Patty W Wright; Sara L Van Driest; Eric Farber-Eger; George E Nelson; Thomas R Talbot
Journal:  Clin Infect Dis       Date:  2018-10-15       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.